AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 182 min read$RVMD

Mancini Anthony sold $720K of RVMD

Mancini Anthony (See Remarks) sold 4,615 shares of Revolution Medicines, Inc. (RVMD) at $156.12 ($0.72M total) on 2026-06-16.

Original reporting
SEC EDGAR · Mancini Anthony
Published Jun 18, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RVMD
Neutral
medium confidence
Mentioned
$RVMD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by an officer (Mancini Anthony) with exact shares, price, and post-transaction holdings; it may slightly affect sentiment but lacks fundamental drivers.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is usually not enough to reprice the stock without additional catalysts.

03

What to watch

The filing doesn’t state motivations (taxes, diversification, planned expenses) and provides no follow-on buying or company-specific news, limiting tradable inference.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-18; transaction dated 2026-06-16 (after-hours/next-session read-through).

Background

This is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc. (RVMD).

Company-level read

Ticker impact

$RVMDNeutralMedium confidence
Context

Form 4 shows officer Mancini Anthony sold 4,615 RVMD shares on 2026-06-16 at $156.1192/share for ~$720.5K.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless paired with other negative disclosures.

Evidence & confidence

The article is a primary-source insider transaction with disclosed size and price, but it provides no guidance, operational change, or material event beyond the sale itself.

Market effects

Sector

Minimal; single-company insider sale without sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales are often pre-planned for liquidity/taxes; absence of a stated 10b5-1 plan doesn’t necessarily imply negative expectations.

Key entities

  • issuer
    Revolution Medicines, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Mancini Anthony

    Officer who sold 4,615 shares of RVMD on 2026-06-16.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDMedAI 9/10

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

gurufocus.com3 min